Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder

Mehmet Solakhan; Burak Bilgin

doi:10.5798/dicletip.620366

Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder

Öz

Objective: We aimed to test ocular and systemic safety of mirabegron medication in the treatment of overactive bladder in elderly patients.

Method: A total of 74 patients (40 male, 34 female) with symptoms of overactive bladder admitted to the urology clinic were included in the study. Patients over 60 years old were included. Patients were followed-up for 3 months. Symptom scores (according to OAB-V8 form), intraocular pressure (IOP) readings of right and left eyes, systolic and diastolic blood pressures of the patients were recorded before and after the treatment. At the end of 3 months, all values were re-evaluated and compared with pre-treatment data.

Results: Mean age was 69.48±7.8 years. The symptom score was found to be 18.67 ± 9.87 before the treatment and 9.83 ± 2.71 after 3 months of the treatment (p=0.0001). Right eye mean IOP value was 16.06 ± 2.62 mmHg before treatment and 15.85 ± 2.31 mmHg after treatment (p=0.341). Left eye mean IOP value was 15.96±2.35 mm mmHg before treatment and 15.94±2.21 mm after treatment (p=0.855). Systolic blood pressure measurements were 128.91±11.76 mmHg before treatment and 128.43±11.95 mmHg after the treatment (p=0.110). Diastolic blood pressure measurements were 81.94±9.83 mmHg before the treatment and 81.31±10.14 mmHg after the treatment (p=0.071).

Conclusion: Treatment of overactive bladder with mirabegron 50mg/day is well tolerated and safe in elderly patients.

Anahtar Kelimeler

Overactive bladder; β3-adrenoreceptor agonist; Oculer safety.

Kaynakça

1. Chapel CR, Amarenco G, Lopez Aramburu MA, et all. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013; 32: 1116-22.
2. Thiagamoorthy G, Kotes S, Zacche M, et all. The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder. TherAdv Urol 2016; 8: 38-46.
3. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
4. Tarcan T, Mangır N, Özgür MÖ, et all. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni 2012; 21: 113-16.
5. Geyer O, Bar-Ilan, A., Nachman, R, et all. Beta3-adrenergic relaxation of bovine iris sphincter. FEBS Lett 1998; 429: 356–8.
6. Diebold Y, Rios J.D, Hodges R.R, et all. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest. Ophthalmol. Vis. Sci 2001; 42: 2270–82.
7. Mori A, Miwa T, Sakamoto K, et all. Pharmacological evidence for the presence of functional ocular safety of mırabegron ın healthy volunteers 679 beta (3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 119–126. Steinle J.J, Zamora D.O, Rosenbaum J.T, Granger H.J. Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp. Eye Res 2005; 80: 83–91.
9. Lee C-L, Kuo H-C. Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Lower Urinary Tract Symptoms 2019; 11: 93-97. https://doi.org/10.1111/luts.12224.

10. Gray SL, Anderson ML, Dublin S, et all. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175: 401–7.
11. Chapple C, DuBeau C, Ebinger U, et all. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007 ; 23:2347–58.
12. Wagg A, Arumi D, Herschorn S, et all. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing 2017; 46: 620–6.
13. Chapple CR, Kaplan SA, Mitcheson D, et all. Randomized doubleblind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β (3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.
14. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987–1006.
15. Sung VC, Corridan PG. Acute-angle closure glaucoma as a sideeffect of oxybutynin. Br J Urol 1998; 81: 634–5.
16. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26: 749–67.
17. Turkoglu AR, Yener NP, Coban S, Guzelsoy M, Demirbas M, Demirci H. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Int Urogynecol J 2017; 28: 777-81. doi: 10.1007/s00192-016-3199-x. Epub 2016 Nov 14.
18. Garely AD, Kaufman JM, Sand PK, et all. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). ClinTher 2006; 28: 1935–46.
19. Nambiar AK, Bosch R, Cruz F, et all. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol 2018; 73: 596-609. Doi: 10.1016/j.eururo.2017.12.031. Epub 2018 Feb

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Mehmet Solakhan ^*
0000-0001-9123-9196

Burak Bilgin Bu kişi benim
0000-0001-6332-2371

Yayımlanma Tarihi

16 Eylül 2019

Gönderilme Tarihi

4 Şubat 2019

Kabul Tarihi

29 Temmuz 2019

Yayımlandığı Sayı

Yıl 2019 Cilt: 46 Sayı: 3

DOI

https://doi.org/10.5798/dicletip.620366

IZ

https://izlik.org/JA26RY66UM

Kaynak Göster

RIS / Bibtex

APA

Solakhan, M., & Bilgin, B. (2019). Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. Dicle Medical Journal, 46(3), 429-434. https://doi.org/10.5798/dicletip.620366

AMA

1.Solakhan M, Bilgin B. Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. diclemedj. 2019;46(3):429-434. doi:10.5798/dicletip.620366

Chicago

Solakhan, Mehmet, ve Burak Bilgin. 2019. “Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder”. Dicle Medical Journal 46 (3): 429-34. https://doi.org/10.5798/dicletip.620366.

EndNote

Solakhan M, Bilgin B (01 Eylül 2019) Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. Dicle Medical Journal 46 3 429–434.

IEEE

[1]M. Solakhan ve B. Bilgin, “Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder”, diclemedj, c. 46, sy 3, ss. 429–434, Eyl. 2019, doi: 10.5798/dicletip.620366.

ISNAD

Solakhan, Mehmet - Bilgin, Burak. “Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder”. Dicle Medical Journal 46/3 (01 Eylül 2019): 429-434. https://doi.org/10.5798/dicletip.620366.

JAMA

1.Solakhan M, Bilgin B. Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. diclemedj. 2019;46:429–434.

MLA

Solakhan, Mehmet, ve Burak Bilgin. “Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder”. Dicle Medical Journal, c. 46, sy 3, Eylül 2019, ss. 429-34, doi:10.5798/dicletip.620366.

Vancouver

1.Mehmet Solakhan, Burak Bilgin. Ocular and Systemic Safety of Mirabegron Treatment in Elderly People with Overactive Bladder. diclemedj. 01 Eylül 2019;46(3):429-34. doi:10.5798/dicletip.620366